EPM
BBIO icon

Equitec Proprietary Markets’s BridgeBio Pharma BBIO Stock Holding History

Equitec Proprietary Markets’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$270K Buy
+4,385
New +$136K 0.09% 76

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Equitec Proprietary Markets's BBIO Position: Q1 2020 in Review

Equitec Proprietary Markets opened a new position in BridgeBio Pharma (BBIO) in Q1 2020: 4,385 shares worth $270K. The stake represents 0.09% of the portfolio and ranks #76 among its holdings.

95 funds tracked by Wall St. Rank hold BBIO as of Q1 2020.

  • Equitec Proprietary Markets held 4,385 shares of BridgeBio Pharma worth $270K as of Q1 2020.
  • BridgeBio Pharma was a new Equitec Proprietary Markets position in Q1 2020.
  • BridgeBio Pharma made up 0.09% of Equitec Proprietary Markets's portfolio in Q1 2020, its #76 holding.
  • 95 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2020.

Based on Equitec Proprietary Markets's 13F filing for Q1 2020, filed 19 Apr 2021.